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AbstrACt
Introduction The recently developed protoporphyrin 
IX- triple state lifetime technique measures mitochondrial 
oxygenation tension (mitoPO2) in vivo at the bedside. 
MitoPO2might be an early indicator of oxygen disbalance 
in cells of critically ill patients and therefore may 
support clinical decisions regarding red blood cell (RBC) 
transfusion. We aim to investigate the effect of RBC 
transfusion and the associated changes in haemoglobin 
concentration on mitoPO
2 and other physiological 
measures of tissue oxygenation and oxygen balance in 
critically ill patients with anaemia. We present the protocol 
and pilot results for this study.
Methods and analysis We perform a prospective 
multicentre observational study in three mixed intensive 
care units in the Netherlands with critically ill patients 
with anaemia in whom an RBC transfusion is planned. 
The skin of the anterior chest wall of the patients is 
primed with a 5- aminolevulinic acid patch for 4 hours for 
induction of mitochondrial protoporphyrin- IX to enable 
measurements of mitoPO
2, which is done with the COMET 
monitoring device. At multiple predefined moments, before 
and after RBC transfusion, we assess mitoPO2 and other 
physiological parameters of oxygen balance and tissue 
oxygenation. Descriptive statistics will be used to describe 
the data. A linear mixed- effect model will be used to study 
the association between RBC transfusion and mitoPO
2 
and other traditional parameters of oxygenation, oxygen 
delivery and oxygen balance. Missing data will be imputed 
using multiple imputation methods.
Ethics and dissemination The institutional ethics 
committee of each participating centre approved the study 
(reference P16.303), which will be conducted according to 
the 1964 Helsinki declaration and its later amendments. 
The results will be submitted for publication in peer- 
reviewed journals and presented at scientific conferences.
trial registration number NCT03092297.
IntroduCtIon
Adequate tissue oxygen delivery is one of 
the cornerstones of therapy in critical care 
medicine. However, direct measurements of 
tissue oxygen oxygenation that would inform 
the clinical assessment of critically ill patients 
at the bedside are lacking.1 Currently, we 
strengths and limitations of this study
 ► The study includes consecutive, critically ill patients 
with severe anaemia receiving red cell transfusions 
that ensure generalisability to patients in whom ox-
ygenation monitoring at the cellular level is most 
relevant.
 ► In addition to all the macrocirculatory measure-
ments for tissue oxygenation in critically ill patients, 
the study will examine bedside oxygenation at the 
cellular level with the mitochondrial oxygenation 
tension (mitoPO
2).
 ► Measurements are done at various timepoints before 
and after red blood cell transfusion that will gener-
ate data on whether changes in cellular oxygenation 
parameters—as assessed with mitoPO
2—precede 
changes in macrocirculatory measurements for tis-
sue oxygenation.
 ► The diagnostic value of mitoPO2 cannot be validated 
against a gold standard, because this is the first test 
to measure cellular oxygenation in patients.
 ► Patients in need of an immediate transfusion cannot 
be included, because the measurement can only be 
performed 4 hours after application of the patch.
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monitor tissue oxygenation by measuring global oxygen 
delivery,1 2 and one of the most important determinants 
of global oxygen delivery is haemoglobin (Hb). In clinical 
practice, Hb is used as a surrogate marker for the need 
for red blood cell (RBC) transfusion to treat an oxygen 
deficit, but personalised Hb concentrations at which 
oxygen deficits exist are still uncertain. Furthermore, 
transfusion does not necessarily improve tissue oxygen-
ation, indicating that other oxygenation parameters are 
needed to determine the need for RBC transfusion.3
A series of new techniques have been developed to quan-
tify oxygen content in the microcirculation and within 
the cell.1 2 4 The protoporphyrin IX- triple state lifetime 
technique (PpIX- TSLT) measures mitochondrial oxygen 
tension (mitoPO2) through the oxygen- dependent optical 
properties of protoporphyrin IX (PpIX).5 6 Thus far, the 
potential of PpIX- TSLT as an early indicator of oxygen 
deficit in the cell has been shown in animal models,7–9 
where after the feasibility has been studied in healthy 
volunteers,10 11 patients undergoing gastroscopy12 and in 
a neurosurgical patient.13 Its ability to measure mitoPO2 
has also been validated in vivo in various organs and 
tissues.5 8 9 14 However, whether PpIX- TSLT can be used to 
measure cellular oxygenation in critically ill patients has 
not been assessed yet.
We aim to investigate the effect of RBC transfusion 
on mitoPO2and the association between mitoPO2 and 
other physiological parameters of oxygen balance and 
tissue oxygenation in anaemic critically ill patients. In 
this report, we describe the study protocol of this obser-
vational study, the study programme in terms of pilot and 
main study and how preliminary results of the pilot study 
resulted in adjustment of the main study design.
MEthods And AnAlysIs
This manuscript was written in accordance with the Stan-
dard Protocol Items Recommendations for Interven-
tional Trials.
study design and setting
The INsufficientOXygenation in ICU patients-2 is a 
multicentre observational cohort study running in three 
academic hospital intensive care unit (ICU) departments 
in the Netherlands: Leiden University Medical Center, 
Amsterdam University Medical Center and Erasmus 
University Medical Center Rotterdam. The participating 
ICUs are all ICUs with a mixed medical and surgical 
patient population. Enrolment for this study started in 
May 2017 for the pilot study solely in Leiden University 
Medical Center, after which enrolment for the main 
study started in March 2018. The pilot study was designed 
to investigate whether crucial components of the main 
study—such as the measurement of mitoPO2 in critically ill 
patients with anaemia and inclusion of eligible patients—
were feasible and aimed to predict an appropriate sample 
size for the full- scale project and to improve the study 
design. The study was registered in  ClinicalTrials. gov 
prior to study enrolment. Informed consent is asked by a 
study team member or a trained treating physician when 
a critically ill patient is admitted to the ICU, regardless 
of having a RBC transfusion decision. This procedure, of 
already having the informed consent instead of asking for 
informed consent when the decision to transfuse is made, 
was chosen to minimise the delay of RBC transfusion while 
waiting for informed consent, in case a blood transfusion 
is needed at some point during ICU admittance. Partic-
ipant and legal representatives can always decline study 
participation at any time for any reason. Data collected 
up to that point will be used, and no further data will be 
collected.
Patient and public involvement
The public and patients were not involved in the prepara-
tion and design of the study. The results of the study will 
be disseminated to study participants via a letter after the 
study has ended.
Eligibility criteria
Critically ill patients with anaemia with an arterial cath-
eter in situ receiving a single RBC unit to correct a Hb 
threshold of 10 g/dL or lower are included. Patients 
younger than 18 years, in need of an emergency RBC 
transfusion, without a legal representative, with a brown 
plaster allergy, with photodermatosis and/or porphyria 
or pregnant women are excluded. Furthermore, patients 
with expected admittance <24 hours, without a central 
venous catheter in situ and without sufficient Dutch 
language comprehensibility are excluded. Due to logis-
tics, patients can only be included during working hours 
(08:00 to 18:00) from Monday to Friday.
study procedures
In the Leiden University Medical Center, the local trans-
fusion guideline states that transfusion should be guided 
by the Hb concentration, American Society of Anesthesi-
ologist Classification, age of patient, cardiac state, pulmo-
nary state and volemic state,15 16 resulting in varying 
transfusion thresholds between 6.5 g/dL and 9.7 g/dL. In 
the Amsterdam University Medical Center and Erasmus 
University Medical Center Rotterdam, the local trans-
fusion guideline states that an Hb threshold below 7 g/
dL should be used in all patients.17 Treating physicians 
immediately inform the investigators when they decide to 
give RBC transfusion to critically ill patients with anaemia 
during working hours. After assessment of eligibility 
criteria by the investigator and presence of informed 
consent, the patient is included in the study. The anterior 
chest wall of the patient is cleaned with alcohol, and a 
5- aminolevulinic acid (ALA) containing patch (Alacare, 
Photonamic GmbH, Wedel, Germany) is placed on the 
sternum. The RBC transfusion is given 4 hours after 
administration of this patch to secure that enough PpIX 
is formed. In the participating centres, the time between 
the decision to transfuse and the actual transfusion is 
between 2 and 3 hours; thus, for patients included in our 
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study, the delay to transfusion will be on average 1–2 hours 
longer than in standard care. After extensive discussion 
about the effect of delay on the patient, we concluded 
that 1–2 hour delay in RBC transfusion, which is only one 
of the many interventions ICU patients receive, would 
not significantly affect the outcome. To not influence the 
clinical management in these critically ill patients, the 
treating physician, not the researcher, will always have 
the final say in timing of the RBC transfusion. If clinical 
judgement is that the patient is in need of RBC transfu-
sion before 4 hours of PpIX formation, the patient will be 
excluded from the study. Each RBC transfusion is given 
over a period of 30–60 min.
Four hours after induction of PpIX, the ALA patch 
is removed, and mitoPO2is measured with a probe that 
is placed lightly on the part of the skin where PpIX was 
induced and that is attached to the COMET monitor 
(Photonics Healthcare, Utrecht, the Netherlands, CE 
marked but not yet approved by the U.S. Food and Drug 
Administration). The mitoPO2 measurement is validated 
first by occlusion of the microcirculation, by applying 
local pressure on the measurement probe. In doing 
this, an immediate drop in mitoPO2 level is expected, 
as well as a fast recovery after release of the pressure on 
the microcirculation.13 After this validation procedure, 
mitoPO2 is measured once per minute for 5 min to obtain 
a mean mitoPO2. The measurement of mitoPO2 is thus 
a non- invasive measurement and can be safely used in 
humans.13 To minimise the effect of different light condi-
tions on the PpIX utilisation during all measurements, 
the room lights are turned off. Directly following the 
mitoPO2 measurement, the ALA patch is re- placed on 
the skin to protect the exposed skin against phototoxicity. 
After completion of the last measurement, after the last 
timepoint, the exposed skin is protected from sunlight 
for an additional 24 hours. During the pilot study, we 
had eight timepoints for mitoPO2 measurements: before 
transfusion, at the end of transfusion, 15, 30, 60, 120 and 
180 min after transfusion and 24 hours after transfusion. 
The RBC transfusion is neither unnecessary delayed nor 
administered for the purpose of the study, and only the 
treating physicians have the final decision to administer 
blood. Besides these study interventions, care was deliv-
ered according to local standard and protocolised prac-
tice in the three participating centres.
description of the PpIX-tslt measurement
The PpIX- TSLT measurement has been described in 
detail elsewhere.5 In short, PpIX is a porphyrin synthe-
tised in the mitochondria as a final precursor of heme. 
Conversion of PpIX to haem is a rate limiting step, so 
exogenous administration of ALA, a precursor of PpIX, 
leads to intramitochondrial accumulation of PpIX. In 
skin, 4 hours is needed to induce a PpIX level with a valid 
delayed fluorescence signal.13 After photoexcitation of 
PpIX with a pulse of light of 515 nm from the COMET 
monitor, PpIX, normally in a singlet state, turns into its 
triplet state. The spontaneous relaxation process of PpIX 
to ground state results in emission of delayed fluorescence 
(630–700 nm), but excited PpIX can transfer its energy to 
oxygen and fall back to the ground state without emission 
of light. Due to such oxygen- dependent quenching, the 
delayed fluorescence lifetime is a measure of mitoPO2, 
that is, the more oxygen is present, the shorter is the 
extinction time of the delayed fluorescence signal. With 
every increase or decrease of skin temperature in degrees 
Celsius, an increase or decrease in this oxygen- dependent 
quenching constant is seen.18 The detection of delayed 
fluorescence is a delicate process, since the signal in itself 
is weak, which is overcome by a pulsed excitation with a 
q- switched laser in combination with time- gated detec-
tion.5 After calculating the delayed fluorescence lifetime 
from the acquired signal, the mitoPO2of the measure-
ment site can be calculated using the Stern- Volmer equa-
tion.5 The necessary calibration constants, the quenching 
constants, were validated in rat skin,14 19 rat liver8 and 
rat heart.9 The measurement location is limited to the 
epidermis layer since topical ALA skin penetration is 
possible until a depth of maximum 0.6 mm.13 20 There-
fore, it is not expected that body fat tissue will affect the 
mitoPO2 measurement. However, the possible effect of 
oedema on mitoPO2 measurement cannot be ruled out.
11 
There is a risk of PpIX clearance with each measurement, 
possibly leading to a decline in fluorescence signal, which 
is also known as photobleaching.21 However, the COMET 
uses a light dose less than 2 mJ/cm2per measurement. 
Therefore, the influence of PpIX photobleaching on 
the mitoPO2 measurement, even after repeated measure-
ments, is expected to be negligible and appeared no prac-
tical problem in previous studies until now.22 23
Primary aim
To assess whether crucial components of the main 
study—such as the measurement of mitoPO2 in critically 
ill patients with anaemia—are feasible, we performed 
a pilot study in 20 critically ill patients with anaemia. 
There is no non- invasive golden standard of mitoPO-
2measurement to compare the COMET performances 
with. Hence, feasibility is pragmatically determined by 
the following two parameters: a PpIX- TSLT signal quality 
>25% and a within- subject variability <5 mm Hg. Signal 
quality is measured with the COMET monitor device, in 
which a higher signal quality corresponds to a stronger 
PpIX signal and a more sensitive mitoPO2 measure-
ment. Signal- to- noise ratio (SNR) in time domain life-
time measurements (as implemented in the COMET) is 
commonly defined as the ratio of maximal signal ampli-
tude (at the start of the decay) to the maximum signal 
of the noise (peak- to- peak). Since SNR is not regarded 
as an intuitive measure for the end user of the COMET 
device, the software converts SNR to signal quality using 
a non- linear relationship in which, for example, an 
SNR of 100 provides a signal quality of almost 80%. In a 
previous study, it was shown that for PpIX- based delayed 
fluorescence measurements, an SNR >20 limits the noise- 
induced potential error in mitoPO2 measurements below 
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2% over the physiological PO2 range.
24 A signal quality of 
25% corresponds to an SNR of 20.24Therefore, we chose 
to (arbitrarily) define 25% as the minimum required 
signal quality for a feasible measurement. Within- subject 
variability is defined as the variation of mitoPO2 within 
the subject at each measurement timepoint. The mean 
mitoPO2with its corresponding SD is calculated per 
participant at each timepoint. The mean SD per time-
point therefore represents the within- subject variability 
of the study population per timepoint. Pragmatically, a 
within- subject variability up to 5 mm Hg is defined as a 
feasible measurement to account for possible measure-
ment errors.
The main aim of the study is to assess the effect of 
RBC transfusion on mitoPO2 and to describe the associ-
ation between mitoPO2 and traditional parameters used 
to measure oxygenation, oxygen delivery and oxygen 
balance (ie, central venous oxygen saturation, arte-
rial oxygen saturation, arterial oxygen tension, central 
venous- to- arterial carbon dioxide difference, cardiac 
output and lactate).
secondary aims
Other aims include safety of mitoPO2 measurements, for 
which adverse and serious adverse events are recorded, 
and the description of the association of cutaneous 
mitoPO2 with vital organ functions. Vital organ function is 
assessed by troponin and ischaemic changes on an ECG, 
24- hour urine creatinine, Glasgow Coma Scale and Inten-
sive Care Delirium Screening List score and the arterial 
oxygen tension/fraction inspired oxygen ratio.
data collection
Data is extracted from the hospital’s electronic patient 
dossier system by the coordinating investigator and 
coded to ensure anonymity of the patients. Recorded 
data include age, sex, comorbidities, body mass index, 
reason of ICU admission and Acute Physiology and 
Chronic Health Evaluation (APACHE) II25 and IV26 27 
score. The reason of ICU admission is recorded in accor-
dance with the APACHE IV scoring system.26 With each 
mitoPO2 measurement, the following parameters are 
assessed: heart rate, blood pressure, central venous pres-
sure, peripheral oxygen saturation, body temperature, 
cardiac output, arterial lactate, central venous oxygen 
saturation, arterial oxygen saturation, arterial oxygen 
tension and central venous- to- arterial carbon dioxide 
difference. Cardiac output is assessed by a limited inva-
sive method, the Vigileo/FloTracsystem.28 Information 
regarding use and dosage of noradrenalin, adrenalin, 
phenylephrine, dobutamine, dopamine, milrinone and 
enoximone are collected with each mitoPO2 measure-
ment. In addition, Sequential Organ Failure Assessment 
(SOFA) score,29 the need for mechanical ventilation and 
the amount of fractional inspired oxygen on the day of 
transfusion and 1 day after transfusion are also recorded. 
Data regarding RBC transfusion are recorded as well, 
including timing of RBC transfusion, infusion duration, 
number of RBC transfusions, history of RBC transfusions 
and product code of the RBC units. Clinical outcome 
data are extracted from the electronic health record in 
the 3- month follow- up time and include ICU length of 
stay, hospital length of stay, ICU mortality and in- hospital 
mortality. Critically ill patients will be observed during 
study participation and afterwards for the possible side 
effects of the ALA plaster. We will collect and report data 
regarding adverse events, serious adverse events and 
suspected unexpected serious adverse reactions to gain 
insight in the safety of the mitoPO2 measurement.
Missing data
After the last recruitment, data will be reviewed to check 
for outliers and missing data. Multiple imputation will be 
used to handle missing data.30
statistical analysis of the pilot study
Descriptive statistics was used to describe the characteris-
tics of the study population. The mitoPO2 at the different 
timepoints before and after transfusion were described 
with medians and IQRs or as means with SD depending 
on the distribution of the data. For each timepoint, the 
mean of all five measurements of mitoPO2was calculated 
with a corresponding SD for each patient. These patient- 
specific means were used to calculate the population 
mean at each timepoint. The SDs of the patient- specific 
means at each timepoint were used to calculate the 
within- subject variability, which is the mean of these SDs 
at each timepoint. Signal quality of the mitoPO2 measure-
ment was described using the mean and SD of the signal 
quality.
results of the pilot study
The pilot study was performed between May and August 
2017. During the 3- month study period, 233 RBC trans-
fusions were given to 114 patients (figure 1). After assess-
ment of eligibility criteria, 20 patients were included in 
the pilot study.
In two study participants, no consecutive mitoPO2 
measurements were possible due to discharge from the 
ICU. The delayed fluorescence signals were detected in all 
but one patient who had a large amount of red- coloured 
chlorhexidine on the chest after cardiothoracic surgery, 
despite cleaning the skin with alcohol. A large amount 
of red- coloured chlorhexidine possibly influences the 
delayed fluorescence detection, thereby leading to a low 
signal quality. The demographic data of the 18 included 
patients in the analysis can be found in table 1.
The mean mitoPO2 before start of RBC transfusion 
was 70.5 mm Hg (SD 13 mm Hg), which largely corre-
sponded with the mean mitoPO2 value in healthy volun-
teers (mean 66.3 mm Hg, SD 16 mm Hg).11 Since there 
is no known normal range of mitoPO2, interpretation 
needs to be performed cautiously. Reliable signals were 
detectable in all remaining patients (n=18), with a signal 
quality above 25% during all the measurements (table 2). 
The within- subject variability of mitoPO2 was 3.0 mm Hg 
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Figure 1 Flow diagram of enrolment of study participant for 
the pilot study of the INOX ICU-2 study. ICU, intensive care 
unit; INOX- ICU-2, INsufficient OXygenation in ICU patients-2; 
RBC, red blood cell.
Table 1 Demographic and admission characteristics of the 
study participants
Characteristic
Values are median (IQR) 
or number (%)
Age in years, mean±SD 65.3±13.9
Male sex 13 (72.2)
BMI, mean±SD 26.3±4.2
Admission reason (according to APACHE IV)
  Surgical 7 (38.9)
  System 1 (14.3)
  Cardiovascular 6 (85.7)
  Respiratory 0 (0)
  Digestive 0 (0)
  Neurosurgery 0 (0)
  Genitourinary 0 (0)
  Trauma 0 (0)
  Miscellaneous 0 (0)
  Non- surgical 11 (61.1)
  Cardiovascular 1 (9.1)
  Respiratory 5 (45.5)
  Sepsis 3 (27.3)
  Neurological 1 (9.1)
  Miscellaneous 1 (9.1)
Chronic comorbidities (according 
to APACHE IV)
8 (44.4)
  Chronic cardiovascular 
insufficiency
0 (8.3)
  Chronic obstructive lung 
disease
1 (8.3)
  Chronic respiratory 
insufficiency
1 (8.3)
  Chronic renal insufficiency 1 (8.3)
  Haematological malignancy 4 (33.3)
  Immunological deficiency 2 (16.7)
  Diabetes mellitus 3 (25)
Days already admitted to ICU 4 (2–11)
APACHE II score 23.5 (20–30)
APACHE IV score 86 (73–103)
SOFA score 8 (4–11)
Baseline Hb in g/dL 7.7 (7.3–7.9)
Baseline Ht in L/L 0.237 (0.220–0.246)
Number of patients using 
vasopressors
9 (50)
Number of patients with a central 
venous catheter in place
16 (88.9)
Number of red cell transfusions 1.0 (1–1)
Number of patients receiving 
RBC before inclusion
16 (88.9)
Continued
before RBC transfusion, 5.8 mm Hg 30 min after RBC 
transfusion, 3.6 mm Hg 2 hours after RBC transfusion, 
7.3 mm Hg 3 hours after RBC transfusion and 8.7 mm Hg 
24 hours after transfusion (table 3). No adverse or serious 
adverse events regarding the ALA patch were observed 
by the patient, family, nurse, investigators or physician 
during the mitoPO2 measurements and 1 day after the 
measurements.
The within- subject variability in this study seems to tally 
with the observed within- subject variability in healthy 
volunteers.11 However, there were no data on the course 
of within- subject variability over time in the healthy 
volunteers. The observed increase in the within- subject 
variation in mitoPO2 values over time may have been 
due to decreased measurement sensitivity, despite having 
adequate signal quality. Alternatively, other interventions 
that were performed besides a RBC transfusion in criti-
cally ill patients may have contributed to the variation. To 
assess this further, a separate study will assess the 24- hour 
course of mitoPO2 in healthy volunteers and in critically 
ill patients who receive minimal ICU interventions and 
no RBC transfusion.
sample size estimation
To the best of our knowledge, no previous data on 
mitoPO2values in critically ill patients with anaemia were 
available. We used data from our pilot study among 20 
subjects to calculate the mean and SD of mitoPO2 in the 
target population to subsequently calculate the sample 
size. With a p value for statistical significance of 5% and a 
statistical power of 90%, a mean mitoPO2of 67.9 mm Hg 
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Characteristic
Values are median (IQR) 
or number (%)
Number on mechanical 
ventilation during study
5 (27.8)
Baseline fractional inspired oxygen in %
  Mechanically ventilated 
patients
45 (40–50)
  Non- mechanically ventilated 
patient
28 (21–42)
Mortality in ICU during follow- up 5 (27.8%)
APACHE, Acute Physiology and Chronic Health Evaluation; 
BMI, body mass index; Hb, haemoglobin; Ht, haematocrit; ICU, 
intensive care unit; RBC, red blood cell; SOFA, Sequential Organ 
Failure Assessment.
Table 1 Continued
Table 2 Overview of signal quality of the mitoPO2 
measurements
Measurement moment Median in % IQR
Before RBC transfusion 35.25 33.00–48.00
At the end of RBC transfusion 35.89 32.38–42.08
15 min after RBC transfusion 37.70 32.75–46.57
30 min after RBC transfusion 41.00 37.44–67.67
60 min after RBC transfusion 37.08 35.50–38.50
120 min after RBC transfusion 37.92 32.58–48.93
180 min after RBC transfusion 41.80 35.85–63.36
24 hours after RBC transfusion 46.00 34.00–64.50
mitoPO2, mitochondrial oxygen tension; RBC, red blood cell.
Table 3 The within- subject variability of mitochondrial 
oxygen tension per measurement moment
Measurement moment
Mean mitoPO2 
(mm Hg)
Mean SD 
of mitoPO2 
(mm Hg)
Before RBC transfusion 70.5 3.0
At the end of RBC transfusion 68.1 3.4
15 min after RBC transfusion 69.5 3.5
30 min after RBC transfusion 68.4 5.8
60 min after RBC transfusion 68.1 4.6
120 min after RBC transfusion 70.0 3.6
180 min after RBCtransfusion 67.5 7.3
24 hours after RBCtransfusion 90.0 8.7
The within- subject variability is stable until 2 hours after RBC 
transfusion, after which the within- subject variability increases 
above the pragmatic margin of 5 mm Hg.
mitoPO2, mitochondrial oxygen tension; RBC, red blood cell.and a SD of 13 mm Hg, we need 150 subjects to show a 
change in mitoPO2 of at least 13 mm Hg after RBC trans-
fusion, taking into account an expected 10% attrition 
rate.
statistical analysis of the main study
Descriptive statistics will be used to describe the charac-
teristics of the study population. The following baseline 
characteristics of the study population will be shown: 
age in years, sex, body mass index, reason of admission 
according to APACHE IV criteria,26 chronic comorbidities 
according to APACHE IV criteria,26 days of admission to 
the ICU before inclusion, APACHE II score, APACHE IV 
score, baseline SOFA score, baseline Hb, baseline haema-
tocrit and the number of red cell transfusions given.
Linear mixed- effect models will be used to examine 
the effect of RBC transfusion on mitoPO2and on other 
traditional parameters of oxygenation, oxygen delivery 
and oxygen balance.31 The following parameters will be 
added to the linear mixed- model: age (continuous), sex 
(dichotomous), vasopressor use (dichotomous), inotropic 
therapy (dichotomous), skin temperature (continuous), 
body temperature (continuous), fluid balance (contin-
uous), mechanical ventilation (dichotomous), Hb level 
(continuous), peripheral oxygen saturation (contin-
uous), cardiac index (continuous) and partial arterial 
oxygen pressure (continuous). Skin temperature at the 
measurement site is measured by the COMET device 
and taken into account in the analysis, since it is a known 
factor influencing PpIX formation.20 Oedema at measure-
ment site is taken into account in the analysis by a prag-
matic proxy measurement: the fluid balance. The choice 
of the above factors was determined by the fact that the 
mitoPO2 reflects a balance between oxygen delivery and 
oxygen consumption.5 Oxygen delivery to the tissue can 
be impaired by anaemia, arterial oxygen desaturation, 
low cardiac output and, to a lesser degree, by low partial 
pressure of oxygen.32 The dependence of mitoPO2 values 
on the fractional inspired oxygen concentration has been 
demonstrated in animal studies.7 24 Furthermore, oxygen 
delivery and extraction can be influenced by vasopressor 
and/or inotropic therapy due to vasoconstriction or vaso-
dilatation of the microcirculation.33 Oxygen consump-
tion is influenced by the level of metabolic rate, which is 
influenced for example by hyperthermia, an inflamma-
tory state, stress, pain and mechanical ventilation.32 The 
analysis will be performed in the whole population and in 
subgroups of Hb level before transfusion (Hb level ≤7 g/
dL or Hb level >7 g/dL, as well as in subgroups according 
to disease severity and/or presence of shock).
EthICs And dIssEMInAtIon
Institutional review board approval
The institutional ethics committee of each participating 
centre approved the study (reference P16.303), which is 
conducted according to the 1964 Helsinki declaration and 
its later amendments. Amendments are changes made to 
the study after a favourable opinion by the accredited 
institutional ethics committee has been given. All amend-
ments first have to be approved by the institutional ethics 
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committee of Leiden University Medical Center before 
any changes can be made and communicated to the 
other participating centres. The latest amendment is 
study protocol version 5.0 of 27 February 2019, which has 
been approved by the institutional ethics committee. This 
research is financially supported by Grant PPOC-16–31 by 
Sanquin Research, Amsterdam, the Netherlands.
data handling and dissemination plan
All patients are assigned a random patient identification 
code after inclusion, which is generated by the electronic 
case report form Castor Electronic Data Capture. The 
code book is stored digitally, with restricted access, and 
encrypted with a password. All handling of personal data 
complies with the EU General Data Protection Regu-
lation and the Dutch Act on Implementation of the 
General Data Protection Regulation. Extracted study data 
will be coded and entered in the electronic case report 
form Castor and stored for further publication. To ensure 
data quality, a data dictionary was made before start of 
the study and implemented digitally in the electronic case 
report, including range checks. Only the coordinating 
investigator, the principal investigators, the study monitor 
and Health and Youth Care Inspectorate will have access 
to the final dataset. Multiple times a year, the study will be 
monitored, and source data verification will be applied 
as depicted in the monitor plan in the study protocol, 
via the independent monitor pool of Leiden University 
Medical Center. No data safety monitoring board was 
set up, as it was deemed unnecessary by an independent 
expert. The study protocol was published before start of 
the study on  clinicaltrials. gov. The results of the study 
will be published in (inter- )national scientific journals 
and guidelines. The International Committee of Medical 
Journal Editors authorship criteria will be used to define 
authors in these publications.
Current status of the main study
One of the main results of the pilot study was that measure-
ment of mitoPO2 levels using the PpIX- TSLT in critically 
ill patients receiving RBC transfusions was feasible, since 
the signal quality was above 25% during all timepoints, 
and the within- subject variability was acceptable in the 
first 2 hours after RBC transfusion. However, the results 
of the pilot study led to three changes in the main study 
design.
First, having a central venous catheter in place was 
dismissed as an inclusion criterion, due to the slow inclu-
sion rate and no influence on the primary outcome.
At the end of the pilot study, we noticed that multiple 
patients were not included in the study, due to not having 
a written informed consent in time (42 out of 114 trans-
fused patients). A second important result of the pilot 
study was therefore a change in the consent procedure. 
Previous research had already shown that approximately 
10% of critically ill patients can make an autonomous 
decision regarding research participation, thus most 
decisions are made by their substitute decision makers 
who are already overwhelmed by the medical informa-
tion concerning their relative and/or loved one. Further-
more, studies have also shown that obtaining contact with 
the substitute decision makers can be difficult, especially 
in narrow time windows for inclusion.34 35 The same 
was seen in our study, and this resulted in a low accrual 
rate and was possibly influencing the generalisability of 
our study. We noticed that nearly all substitute decision 
makers decided positively on participation the second day 
of admittance of their loved one, once the first shock had 
decreased. We therefore introduced deferred consent in 
our study. In principal, we still ask all ICU patients, or 
their substitute, admitted to the ICU and expected to stay 
at the ICU for longer than 24 hours for participation in 
our study. However, if no substitute can be reached in 
person for written informed consent, while the patient 
meets the eligibility criteria, the patient is included in the 
study and deferred informed consent is sought within 
48 hours after inclusion.
The third important result of the pilot study was the 
change in the amount of timepoints. Due to logistic 
problems during the pilot study, the number of time-
points was minimised to 6: before transfusion, at the 
end of transfusion, 30, 60 and 180 min after transfusion 
and 24 hours after transfusion. All of these changes 
were laid down in amendments to the study protocol 
and reviewed by the institutional review board, which 
approved these changes. The main study has started 
in March 2018 and is ongoing. End of recruitment is 
expected halfway 2020.
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